Results 21 to 30 of about 20,923 (159)

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.

PLoS ONE, 2022
Patients with type 2 diabetes who have cardiovascular disease and are receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes.
Haruka Tamura, Yoshinobu Kondo, Kohei Ito, Masanori Hasebe, Shinobu Satoh, Yasuo Terauchi   +5 more
doaj   +1 more source

Investigating the Role of Empagliflozin in the Pathological Progress of Ischemia-Reperfusion Injury in Rat Kidneys: The Involvement of Nitric Oxide [PDF]

Advanced Pharmaceutical Bulletin
Purpose: Renal ischemia-reperfusion (RIR) is a pathological condition that can lead to severe outcomes due to damage to kidney structures. Additionally, oxidative stress is triggered by mitochondrial disruption during reperfusion, potentially resulting ...
Amin Hasanvand, Abdolreza Tajdar, Azita Zafar Mohtashami, Zahra Haghighatian, Elham Goodarzi, Peyman Amanolahi Baharvand, Babak Hadian   +6 more
doaj   +1 more source

Efficacy and Safety of Empagliflozin in Type 1 Diabetes Mellitus Patients: A Systematic Review

Endocrinology Research and Practice, 2021
As the efficacy and safety of empagliflozin remain poorly studied in Type 1 diabetes mellitus (T1DM) patients, this narrative-systematic review aims to review it.
Sumanta SAHA, Sujata SAHA
doaj   +1 more source

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Journal of Immunology Research, 2021
Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases ...
Nami Lee, Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim   +8 more
doaj   +1 more source

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

Frontiers in Pharmacology, 2022
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and ...
Alana Aragón-Herrera, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Manuel Campos-Toimil, Tomás García-Caballero, Luis Barral, Estefanía Tarazón, Estefanía Tarazón, Esther Roselló-Lletí, Esther Roselló-Lletí, Manuel Portolés, Manuel Portolés, Oreste Gualillo, Isabel Moscoso, Ricardo Lage, José Ramón González-Juanatey, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Sandra Feijóo-Bandín, Francisca Lago, Francisca Lago   +22 more
doaj   +1 more source

Linagliptin + Empagliflozin+Metformin.xlsx

, 2023
The dataset has all data about Linagliptin, Empagliflozin, and Metformin with para dimethylaminobenzaldahyde.
lujain sahloul (15476726)
core   +1 more source

Berthold Hocher_Reno-protective Effects of Empagliflozin

, 2023
   The mechanisms of nephroprotection in non-diabetic chronic kidney disease (CKD) models by sodium-glucose cotransporter 2 (SGLT2) inhibitors are not well defined.
Hongwei Wu (1234719), Lianghong Yin (5401373), XIN CHEN (10031207), Mohamed M.S. Gaballa (14142149), Zheyu Zhang (6987899), Linghong Shen (562106), Stanislao Morgera (11828), Yaochen Cao (11477747), Denis Delić (2547817), Berthold Hocher (9256231), Thomas Klein (121443), Qin Shao (562104), Christoph Reichetzeder (316894), Ahmed A. Hasan (10574721), Bernhard K· Krämer (11477749), Ben He (14142151)   +15 more
core   +1 more source

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome

Journal of the Saudi Heart Association, 2017
Clinical Research. Presentation type: Poster Presentation. Introduction: Empagliflozin is a potent and selective SGLT2-I used in the treatment of T2DM.
Mahmoud Elrouby, Elvira Toural
doaj   +1 more source

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

ESC Heart Failure, 2022
Aims In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of
Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P. Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke   +10 more
doaj   +1 more source

Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet‐Derived Growth Factor–Related Signaling

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events. However, the precise mechanisms beyond glycemic control are not fully understood.
Gwo‐Jyh Chang, Wei‐Jan Chen, Yu‐Juei Hsu, Ying‐Hwa Chen   +3 more
doaj   +1 more source